Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company's product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spray for the treatment of menopausal hot flashes related vasomotor symptoms and other women's health indications; PH15, an investigational neuroactive to treat improve psychomotor or cognitive impairment caused by mental fatigue; PH284, an early-stage investigational neuroactive steroid for the treatment of investigational neuroactive pherine nasal spray for the treatments of loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain to treat disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates from a new class of potential neuroscience therapies comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California. more
Time Frame | VTGN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.54% | -2.27% | -0.57% |
1-Month Return | -13.83% | -3.96% | 1.21% |
3-Month Return | -26.14% | -9.7% | 7.57% |
6-Month Return | -30.97% | -3.37% | 11.45% |
1-Year Return | -48.84% | 3.71% | 28.48% |
3-Year Return | -95.5% | 3.8% | 29.52% |
5-Year Return | -88.43% | 39.78% | 90.66% |
10-Year Return | -99.07% | 106.91% | 203.75% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 334.00K | 1.09M | 1.11M | (227.30K) | 1.06M | [{"date":"2020-03-31","value":30.12,"profit":true},{"date":"2021-03-31","value":98.25,"profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-20.5,"profit":false},{"date":"2024-03-31","value":95.95,"profit":true}] |
Cost of Revenue | 103.10K | - | 815.20K | 509.80K | 568.00K | [{"date":"2020-03-31","value":12.65,"profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":62.54,"profit":true},{"date":"2024-03-31","value":69.68,"profit":true}] |
Gross Profit | (103.10K) | 1.09M | 293.70K | (227.30K) | 1.06M | [{"date":"2020-03-31","value":-9.46,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":26.96,"profit":true},{"date":"2023-03-31","value":-20.86,"profit":false},{"date":"2024-03-31","value":97.66,"profit":true}] |
Gross Margin | (30.87%) | 100.00% | 26.49% | 100.00% | 100.00% | [{"date":"2020-03-31","value":-30.87,"profit":false},{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":26.49,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Expenses | 19.97M | 19.02M | 48.66M | 59.04M | 34.09M | [{"date":"2020-03-31","value":33.83,"profit":true},{"date":"2021-03-31","value":32.22,"profit":true},{"date":"2022-03-31","value":82.41,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":57.73,"profit":true}] |
Operating Income | (20.80M) | (17.93M) | (47.78M) | (59.27M) | (33.02M) | [{"date":"2020-03-31","value":-2080150000,"profit":false},{"date":"2021-03-31","value":-1793380000,"profit":false},{"date":"2022-03-31","value":-4777890000,"profit":false},{"date":"2023-03-31","value":-5926800000,"profit":false},{"date":"2024-03-31","value":-3302100000,"profit":false}] |
Total Non-Operating Income/Expense | 60.10K | 4.20K | 39.90K | 52.40K | 7.01M | [{"date":"2020-03-31","value":0.86,"profit":true},{"date":"2021-03-31","value":0.06,"profit":true},{"date":"2022-03-31","value":0.57,"profit":true},{"date":"2023-03-31","value":0.75,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Pre-Tax Income | (20.77M) | (17.93M) | (47.76M) | (59.24M) | (29.36M) | [{"date":"2020-03-31","value":-2077140000,"profit":false},{"date":"2021-03-31","value":-1793160000,"profit":false},{"date":"2022-03-31","value":-4775900000,"profit":false},{"date":"2023-03-31","value":-5924180000,"profit":false},{"date":"2024-03-31","value":-2935800000,"profit":false}] |
Income Taxes | 2.60K | 2.60K | 3.40K | 5.90K | 4.00K | [{"date":"2020-03-31","value":44.07,"profit":true},{"date":"2021-03-31","value":44.07,"profit":true},{"date":"2022-03-31","value":57.63,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":67.8,"profit":true}] |
Income After Taxes | (20.77M) | (17.93M) | (47.76M) | (59.25M) | (29.36M) | [{"date":"2020-03-31","value":-2077400000,"profit":false},{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false}] |
Income From Continuous Operations | (20.77M) | (17.93M) | (47.76M) | (59.25M) | (29.36M) | [{"date":"2020-03-31","value":-2077400000,"profit":false},{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | (20.77M) | (17.93M) | (47.76M) | (59.25M) | (29.36M) | [{"date":"2020-03-31","value":-2077400000,"profit":false},{"date":"2021-03-31","value":-1793420000,"profit":false},{"date":"2022-03-31","value":-4776240000,"profit":false},{"date":"2023-03-31","value":-5924770000,"profit":false},{"date":"2024-03-31","value":-2936200000,"profit":false}] |
EPS (Diluted) | (0.50) | (0.39) | (0.25) | (1.98) | (2.07) | [{"date":"2020-03-31","value":-50,"profit":false},{"date":"2021-03-31","value":-39,"profit":false},{"date":"2022-03-31","value":-25,"profit":false},{"date":"2023-03-31","value":-198,"profit":false},{"date":"2024-03-31","value":-207,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VTGN | |
---|---|
Cash Ratio | 12.97 |
Current Ratio | 13.29 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VTGN | |
---|---|
ROA (LTM) | -39.40% |
ROE (LTM) | -61.52% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VTGN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.91 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VTGN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 79.75 |
P/B | 0.74 |
Price/FCF | NM |
EV/R | 8.05 |
EV/Ebitda | NM |
PEG | NM |
VistaGen Therapeutics Inc (VTGN) share price today is $2.43
Yes, Indians can buy shares of VistaGen Therapeutics Inc (VTGN) on Vested. To buy VistaGen Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VTGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of VistaGen Therapeutics Inc (VTGN) via the Vested app. You can start investing in VistaGen Therapeutics Inc (VTGN) with a minimum investment of $1.
You can invest in shares of VistaGen Therapeutics Inc (VTGN) via Vested in three simple steps:
The 52-week high price of VistaGen Therapeutics Inc (VTGN) is $5.86. The 52-week low price of VistaGen Therapeutics Inc (VTGN) is $2.38.
The price-to-earnings (P/E) ratio of VistaGen Therapeutics Inc (VTGN) is
The price-to-book (P/B) ratio of VistaGen Therapeutics Inc (VTGN) is 0.74
The dividend yield of VistaGen Therapeutics Inc (VTGN) is 0.00%
The market capitalization of VistaGen Therapeutics Inc (VTGN) is $69.89M
The stock symbol (or ticker) of VistaGen Therapeutics Inc is VTGN